FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer

FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer

Jul 24, 2015
Source URL: https://qa1.novartis.us/us-en/news/media-releases/fda-approves-novartis-drug-odomzo-sonidegib-locally-advanced-basal-cell-carcinoma-labcc-form-skin-cancer-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/fda-approves-novartis-drug-odomzo-sonidegib-locally-advanced-basal-cell-carcinoma-labcc-form-skin-cancer-0